^
    Back
    Association details:
    Biomarker:BTK C481
    Cancer:Small Lymphocytic Lymphoma
    Drug:Jaypirca (pirtobrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2022
    Title:

    PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

    Published date:
    05/12/2022
    Excerpt:
    Pirtobrutinib demonstrated promising efficacy in heavily pretreated CLL/SLL pts following multiple prior lines of therapy and in pts with BTK C481 mutations.
    Trial ID:
    BRUIN
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

    Published date:
    11/04/2021
    Excerpt:
    Pirtobrutinib demonstrated promising efficacy in heavily pretreated CLL/SLL pts following multiple prior lines of therapy, including a covalent BTKi and a BCL2 inhibitor, and in pts with BTK C481 mutations.
    DOI:
    10.1182/blood-2021-147599
    Trial ID:
    BRUIN